Drug Trial Radar · NCT04578834
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
517
Actual
Start
Jan 25, 2021
Primary completion
Sep 19, 2025
Study completion Sep 19, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.
Conditions
- IgA Nephropathy
Interventions
PlaceboDrug
Placebo to LNP023 200mg b.i.d
LNP023Drug
LNP023 200mg b.i.d
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio to Baseline in UPCR at 9 Months - Interim AnalysisTime frame: Baseline and 9 months
- Annualized Total eGFR Slope Estimated Over 24 Months - Final AnalysisTime frame: 24 months
Locations
177 sites in 35 countries. Site status is shown where the registry gives one.
AZ Kidney Dise and Hypertension Ctr
Glendale, Arizona
AKDHC Medical Research ServicesLLC
Phoenix, Arizona
UCLA Medical Center
Los Angeles, California
Kaiser Permanente
San Diego, California
North America Research Institute
San Dimas, California
University of Colorado Anschutz
Aurora, Colorado
Nephrology Associates PA
Newark, Delaware
Boise Kidney and Hypertension
Boise, Idaho
CaRe Research
Chubbuck, Idaho
Nep Assoc of Northern Illinois
Hinsdale, Illinois
Renal Associates of Baton Rouge
Baton Rouge, Louisiana
Johns Hopkins Hospital
Baltimore, Maryland
Brigham and Womens Hosp Harvard Med School
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Clin Rsrch Consult a JCCT Company
Kansas City, Missouri
DaVita Clinical Research
Las Vegas, Nevada
New Jersey Kidney Care
Jersey City, New Jersey
Columbia University Irving Medical
New York, New York
Dallas Renal Group
Dallas, Texas
Prolato Clinical Research Center
Houston, Texas
Univ of Washington Medi Cen
Seattle, Washington
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
St Albans, Victoria, Australia
Novartis Investigative Site
Edegem, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Roeselare, West Vlaanderen, Belgium
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
São José do Rio Preto, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.